Business Wire

TRADE-EXTENSIONS

7.12.2016 15:45:52 CET | Business Wire | Press release

Share
Trade Extensions: Consumers put their trust in manufacturers and retailers to look after suppliers

Consumers put their trust in manufacturers and retailers to look after suppliers and are prepared to pay more to shop at retailers who treat their suppliers better.

The latest research from sourcing with optimisation specialist Trade Extensions reveals the implicit trust consumers place in manufactures and retailers to look after supplier welfare and the penalties retailers face should they betray this trust.

The research reveals that while only 20% of UK and US consumers ranked suppliers as the most important consideration at the point of purchase, 76% feel manufacturers and retailers have a responsibility to look after suppliers and only 9% feel that manufacturers and retailers have no responsibility.

This implicit trust that consumers place in manufacturers and retailers is further demonstrated by the fact that 75% say they would prefer to shop at a retailer if it can demonstrate they treat their suppliers better and over 75% of consumers are prepared to pay a premium. In addition, only 25% of consumers feel the government should get involved in supplier welfare.

Trade Extensions, CEO, Garry Mansell, said “Companies often talk about the ‘trust’ that exists between consumers and their brands and sometimes this ‘trust’ feels intangible. However, what this research shows us is when trust is broken, consumers let companies know very quickly by taking their custom elsewhere.”

In addition, consumers are also prepared to pay a premium if a retailer can demonstrate they treat their suppliers better than their competitors. Overall, 76% of consumers are willing to pay more and 28% will pay between 5% - 10% extra and 17% are prepared to pay an additional 10%.

Mansell said, “It is clear that consumers expect suppliers to be treated well and they are prepared to pay extra. Good buyers manage their suppliers in a sustainable way and while buyers and suppliers need each other, they both need the end consumers to be happy as well.”

-ends-

Editor’s Notes

The Trade Extensions ‘Research Bulletin’ series looks at sourcing and supply issues from the point of view of the end consumers and allows supply chain professionals to get into the mind of their ultimate customer.

Download the report here:

https://tradeextensions.com/s/Trade-Extensions-Research-Bulletin-October-2016.pdf

About Trade Extensions

Trade Extensions (www.tradeextensions.com ) specialises in strategic sourcing with optimisation and its platform, TESS™, is used to run projects ranging from routine sourcing, such as simple reverse auctions, to advanced projects involving goods and services worth billions of dollars, millions of data items and multiple rounds of negotiation. Over $1 billion worth of spend is allocated through TESS™ each week.

Trade Extensions has offices across Europe and the U.S. Its sourcing platform is used by leading companies including P&G, Tesco, Unilever, Cargill, Coca-Cola, Dow Chemicals, and Kimberly-Clark.

The Trade Extensions logo is a registered trademark of Trade Extensions TradeExt AB.

TESS™ and TESS Academy™ are trademarks of Trade Extensions TradeExt AB.

Contact:

Trade Extensions
Niklas Pettifor
nik.pettifor@tradeext.com
+44 (0)20 8004 3236

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye